ATOS
Price
$0.89
Change
+$0.01 (+1.14%)
Updated
Jun 27 closing price
Capitalization
115.19M
50 days until earnings call
ERNA
Price
$1.85
Change
-$0.05 (-2.63%)
Updated
Jun 27 closing price
Capitalization
13.68M
Interact to see
Advertisement

ATOS vs ERNA

Header iconATOS vs ERNA Comparison
Open Charts ATOS vs ERNABanner chart's image
Atossa Therapeutics
Price$0.89
Change+$0.01 (+1.14%)
Volume$16.36M
Capitalization115.19M
Ernexa Therapeutics
Price$1.85
Change-$0.05 (-2.63%)
Volume$9.34K
Capitalization13.68M
ATOS vs ERNA Comparison Chart in %
Loading...
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. ERNA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Buy and ERNA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (ATOS: $0.89 vs. ERNA: $1.85)
Brand notoriety: ATOS and ERNA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 1519% vs. ERNA: 15%
Market capitalization -- ATOS: $113.61M vs. ERNA: $13.62M
ATOS [@Biotechnology] is valued at $113.61M. ERNA’s [@Biotechnology] market capitalization is $13.62M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileERNA’s FA Score has 0 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • ERNA’s FA Score: 0 green, 5 red.
According to our system of comparison, ATOS is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 6 TA indicator(s) are bullish while ERNA’s TA Score has 4 bullish TA indicator(s).

  • ATOS’s TA Score: 6 bullish, 1 bearish.
  • ERNA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than ERNA.

Price Growth

ATOS (@Biotechnology) experienced а +12.89% price change this week, while ERNA (@Biotechnology) price change was -24.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ATOS is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATOS($115M) has a higher market cap than ERNA($13.7M). ATOS YTD gains are higher at: -5.540 vs. ERNA (-58.050). ATOS has more cash in the bank: 65.1M vs. ERNA (1.92M). ATOS has less debt than ERNA: ATOS (0) vs ERNA (2.88M).
ATOSERNAATOS / ERNA
Capitalization115M13.7M839%
EBITDA-28.04MN/A-
Gain YTD-5.540-58.05010%
P/E RatioN/AN/A-
Revenue0N/A-
Total Cash65.1M1.92M3,394%
Total Debt02.88M-
FUNDAMENTALS RATINGS
ATOS vs ERNA: Fundamental Ratings
ATOS
ERNA
OUTLOOK RATING
1..100
4351
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
5096
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (28) in the Medical Specialties industry is somewhat better than the same rating for ERNA (61). This means that ATOS’s stock grew somewhat faster than ERNA’s over the last 12 months.

ATOS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

ATOS's SMR Rating (97) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

ATOS's Price Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for ERNA (96). This means that ATOS’s stock grew somewhat faster than ERNA’s over the last 12 months.

ATOS's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as ERNA (100). This means that ATOS’s stock grew similarly to ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSERNA
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
72%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 12 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
N/A
Bullish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EBKOF85.372.85
+3.45%
Erste Group Bank AG
AMIVF8.460.20
+2.38%
Atrium Mortgage Investment Corp
HMLPF17.00N/A
N/A
Hoegh LNG Partners LP
HBUV1.30N/A
N/A
Hubilu Venture Corporation
STLJF56.71N/A
N/A
Stella Jones Inc.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with ABOS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
+1.64%
ABOS - ATOS
46%
Loosely correlated
-7.44%
GBIO - ATOS
44%
Loosely correlated
-15.40%
IMNM - ATOS
43%
Loosely correlated
-0.23%
MGNX - ATOS
43%
Loosely correlated
-6.30%
NRIX - ATOS
43%
Loosely correlated
+0.17%
More

ERNA and

Correlation & Price change

A.I.dvisor tells us that ERNA and ATOS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ERNA and ATOS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-2.63%
ATOS - ERNA
28%
Poorly correlated
+1.64%
RNTX - ERNA
26%
Poorly correlated
-4.55%
BDTX - ERNA
25%
Poorly correlated
-4.07%
VSTM - ERNA
25%
Poorly correlated
-0.24%
RAIN - ERNA
25%
Poorly correlated
+5.79%
More